Vectorite Biomedical (ROCO:4170) Ending Cash Position: NT$21.39 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4170 Vectorite Biomedical Inc ROCO:4170
70 GF Score
Price NT$12.45
GF Value NT$13.97
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Vectorite Biomedical Ending Cash Position?

Vectorite Biomedical ROCO:4170 +2.05% 70 Ending Cash Position is NT$21.39 Mil as of Jun. 2026. GuruFocus rates ROCO:4170 with a GF Score™ of 70/100 and a GF Value™ of NT$13.97 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Vectorite Biomedical's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$21.39 Mil.

Vectorite Biomedical's quarterly Ending Cash Position increased from Jun. 2025 (NT$13.91 Mil) to Dec. 2025 (NT$25.71 Mil) but then declined from Dec. 2025 (NT$25.71 Mil) to Jun. 2026 (NT$21.39 Mil).

Vectorite Biomedical's annual Ending Cash Position increased from Dec. 2023 (NT$25.32 Mil) to Dec. 2024 (NT$30.60 Mil) but then declined from Dec. 2024 (NT$30.60 Mil) to Dec. 2025 (NT$25.71 Mil).

Vectorite Biomedical Ending Cash Position Related Terms

Vectorite Biomedical Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Vectorite Biomedical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectorite Biomedical Ending Cash Position Chart

Vectorite Biomedical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.20 27.87 25.32 30.60 25.71

Vectorite Biomedical Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.79 30.60 13.91 25.71 21.39
ROCO:4170
70GF Score
Vectorite Biomedical Inc ROCO:4170
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectorite Biomedical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vectorite Biomedical's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=30.604+-4.894
=25.71

Vectorite Biomedical's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=25.71+-4.32
=21.39

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$21.39 Mil mean?
Vectorite Biomedical (ROCO:4170) has a Ending Cash Position of NT$21.39 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vectorite Biomedical and its competitors.
Is Vectorite Biomedical's Ending Cash Position too high?
Vectorite Biomedical's current Ending Cash Position is NT$21.39 Mil. Overall, Vectorite Biomedical has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Ending Cash Position compare to VRTX and REGN?
Vectorite Biomedical's Ending Cash Position of NT$21.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vectorite Biomedical and its competitors. Vectorite Biomedical's current Ending Cash Position is NT$21.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$13.97, compared to a current price of NT$12.45 — trading 10.9% below its estimated fair value. The current Ending Cash Position is NT$21.39 Mil. Vectorite Biomedical's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Ending Cash Position is NT$21.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?

Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued. The current stock price of NT$12.45 is trading 10.9% below its estimated GF Value™ of NT$13.97. GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.

Key valuation signals for ROCO:4170:

  • Ending Cash Position: NT$21.39 Mil
  • GF Value™: NT$13.97 vs. price of NT$12.45 (10.9% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vectorite Biomedical Business Description

Address Number 97, Section 1, Xintai 5th Road, 6th Floor, Floor-11, Yuzhi District, New Taipei City, Taipei, TWN, 22175
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
70GF Score

Get the complete analysis for ROCO:4170

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.45
Price
NT$13.97
GF Value